Targanta’s Noninferiority Study Design Could Be Regulatory Hurdle For Oritavancin
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryTarganta may need to conduct additional clinical trials of its intravenous antibiotic oritavancin if FDA does not accept the company's use of a 15 percent noninferiority delta in its Phase III trial, according to the firm's initial public offering prospectus filed May 11 with the Securities & Exchange Commission.
You may also be interested in...
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.